InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article contentBEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct a Phase II/III clinical trial of novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU).Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentArticle contentSoficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The current indications under development are strategically positioned within the vast dermatology market, including atopic dermatitis, vitiligo, prurigo nodularis, CSU, and more. TYK2 plays a key role in the JAK-STAT signaling pathway and is critical in the pathogenesis of inflammatory diseases.Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentSoficitinib blocks signaling pathways such as lL-4, IL-13, IL-31, and other cytokines that drive mast cell activation and inflammation, reducing itch and wheals in CSU.Article contentCSU is characterized by recurrent wheals and itch, with a disease course typically lasting two to five years, and in some patients, even exceeding five years. China has a large population of CSU patients, a condition that is prone to recurrent episodes. The intense nighttime itching severely disrupts daily life. Long-term, systematic, and standardized treatment is therefore essential for disease control.Article contentThere are approximately 50 million CSU patients worldwide1, and the global CSU treatment market is expected to reach $3 billion in 20292.Article contentArticle contentDr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “InnoCare’s pipeline under development covers ten major autoimmune diseases, with our TYK2 inhibitors deeply positioned in the field of dermatology. We are accelerating the clinical development of soficitinib to address huge unmet medical needs. We hope this innovative drug will benefit more autoimmune disease patients as early as possible.”Article contentAbout InnoCareInnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.Article content1 DOI: 10.1007/s12325-025-03172-02 The Business Research CompanyArticle contentContactArticle contentMediaChunhua Lu86-10-66609879chunhua.lu@innocarepharma.comInvestors 86-10-66609999ir@innocarepharma.comArticle contentArticle contentArticle contentArticle contentArticle contentArticle contentTrending Is a $2.75 million portfolio enough for Halifax empty nesters to retire early?

Personal Finance World watches as Ottawa's bullish shift on LNG puts wind at the back of two major projects Oil & Gas Canada's population declines for the first time since the pandemic News 'Why let one person in the States change your life?' For Canadian snowbirds, the stay or go dilemma gets complicated Real Estate So long, labour shortage: job vacancies continue to decline in Canada Work Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Is a $2.75 million portfolio enough for Halifax empty nesters to retire early?

Personal Finance World watches as Ottawa's bullish shift on LNG puts wind at the back of two major projects Oil & Gas Canada's population declines for the first time since the pandemic News 'Why let one person in the States change your life?' For Canadian snowbirds, the stay or go dilemma gets complicated Real Estate So long, labour shortage: job vacancies continue to decline in Canada Work